|
Match
|
Document |
Document Title |
|
|
US20150023950 |
2,6-Diaminopyridine Compounds Suitable for Treating Diseases Associated with Amyloid or Amyloid-Like Proteins or for Treating or Preventing Ocular Diseases or Conditions Associated with a Pathological Abnormality/Change in the Tissue of the Visual System
The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or... |
|
|
US20110059170 |
METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS
Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the... |
|
|
US20110034442 |
Use and Methods of Use for an Antagonist of the Serotin3 Receptor (5-HT3) and a Selective Modulator of Chloride Channels for the Treatment of Addiction to or Dependence on Medicines/Drugs or Nervous System Disorders
The present invention relates to the composition and methods of using a combination of a serotonin3 (5-HT3) receptor antagonist, such as ondansetron, and a selective chloride channel modulator,... |
|
|
US20130224289 |
GASTRIC RETAINED GABAPENTIN DOSAGE FORM
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. |
|
|
US20120282307 |
GASTRIC RETAINED GABAPENTIN DOSAGE FORM
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. |
|
|
US20120064129 |
GASTRIC RETAINED GABAPENTIN DOSAGE FORM
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. |
|
|
US20130236573 |
ESKETAMINE FOR THE TREATMENT OF TREATMENT-REFRACTORY OR TREATMENT-RESISTANT DEPRESSION
The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a... |
|
|
US20110237563 |
FAST DISSOLVING DRUG DELIVERY SYSTEMS
The present invention related to the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for treating illnesses of patient with critical buccal condition,... |
|
|
US20150119383 |
ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other... |
|
|
US20130245004 |
ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other... |
|
|
US20130143867 |
ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other... |
|
|
US20140162964 |
USE IN BRAIN DEGENERATIVE DISEASES
Disclosed is a new use for sphingosine-1-phosphate (S1P) receptor agonists in the treatment of progressive dementia or brain degenerative diseases. |
|
|
US20120135950 |
ANTIVIRAL TREATMENT OF LYMPHOMA AND CANCER
Compositions and methods to treat lymphoma and cancer are disclosed. In particular, the method teaches treatment of lymphoma and cancer using anti-HERV-K(HML-2) therapies. Further taught are... |
|
|
US20150246067 |
ANTIVIRAL TREATMENT OF LYMPHOMA AND CANCER
The present invention provides compositions and methods to treat lymphoma and cancer. In particular, the present invention provides treatment of lymphoma and cancer using anti-HERV-K(HML-2)... |
|
|
US20120064168 |
METHODS OF TREATMENT USING A GASTRIC RETAINED GABEPENTIN DOSAGE
A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form. |
|
|
US20110009351 |
SCREENING ASSAY TO IDENTIFY CORRECTORS OF PROTEIN TRAFFICKING DEFECTS
The present invention relates to a novel assay or screen for identifying compounds with potential therapeutic value for the treatment of protein trafficking diseases such as Cystic Fibrosis (CF)... |
|
|
US20110028418 |
USE OF GABBA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXCESSIVE SLEEPINESS AND DISORDERS ASSOCIATED WITH EXCESSIVE SLEEPINESS
GABAA receptor mediated hypersomnia can be treated by administering a GABAA receptor antagonist (e.g., flumazenil; clarithromycin; picrotoxin; bicuculline; cicutoxin; and oenanthotoxin). In some... |
|
|
US20110280808 |
Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins
The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and... |
|
|
US20130090329 |
Methods and Compositions for the Treatment of Psychotic Disorders Through the Identification of the Olanzapine Poor Response Predictor Genetic Signature
Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a OPRP genetic... |
|
|
US20120015035 |
Implantable Delivery Vehicle for Ocular Delivery of Muscarinic Antagonists
The present invention provides compositions and methods for treating ocular disorders such as myopia. |
|
|
US20120277211 |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC DISORDERS THROUGH THE IDENTIFICATION OF THE SULT4A1-1 HAPLOTYPE
Methods and compositions that relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1... |
|
|
US20110105469 |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC DISORDERS THROUGH THE IDENTIFICATION OF THE SULT4A1-1 HAPLOTYPE
Methods and compositions that relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1... |
|
|
US20110105468 |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC DISORDERS THROUGH THE IDENTIFICATION OF THE SULT4A1-1 HAPLOTYPE
Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1... |
|
|
US20110105467 |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC DISORDERS THROUGH THE IDENTIFICATION OF THE SULT4A1-1 HAPLOTYPE
Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1... |
|
|
US20110105466 |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC DISORDERS THROUGH THE IDENTIFICATION OF THE SULT4A1-1 HAPLOTYPE
Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1... |
|
|
US20140234443 |
5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF
Novel 5-HT3 receptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and... |
|
|
US20120270857 |
5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF
Novel 5-HT3 receptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and... |
|
|
US20130338149 |
SEDATIVE FOR USE DURING EYE SURGERY
A drug for sedating a patient, and especially a smoker, during eye surgery. The drug includes a sedative such as midazolam in a mix with nicotine. The mixture is injected into the patient prior to... |
|
|
US20110046116 |
SEDATIVE FOR USE DURING EYE SURGERY
A drug for sedating a patient, and especially a smoker, during eye surgery. The drug includes a sedative such as midazolam in a mix with nicotine. The mixture is injected into the patient prior to... |
|
|
US20150174138 |
DIAGNOSTIC AND TREATMENT METHODS IN SUBJECTS HAVING OR AT RISK OF DEVELOPING RESISTANCE TO CANCER THERAPY
The invention relates to methods of treatment and diagnosis of subjects with cancer. In some aspects, the invention relates to methods of treatment and diagnosis of subjects with cancer, wherein... |
|
|
US20130190299 |
METHODS AND COMPOSITIONS FOR TREATMENT OF MULTIPLE SCLEROSIS
Methods and formulations for the treatment of multiple sclerosis with drugs with affinity for both serotonergic 5-HT2 and dopaminergic receptors such as the D2 receptor are herein disclosed.... |
|
|
US20120058186 |
THERAPEUTIC OR PROPHYLACTIC AGENT FOR DYSKINESIA
The present invention relates to a stable orally disintegrating coated tablet containing a drug, wherein the tablet is coated with a coating layer containing a water-soluble substance and a... |
|
|
US20130281440 |
DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO
The invention encompasses methods for treating or preventing diseases and disorders associated abnormal cell growth, for example, treating or preventing cancer or tumor growth, by administering to... |
|
|
US20150031677 |
TRIOXANE THIOACETAL MONOMERS AND DIMERS AND METHODS OF USE THEREOF
Monomeric and dimeric trioxane thioacetals and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic... |
|
|
US20110312946 |
COMBINATION THERAPY FOR THE TREATMENT OF DIABETES
The present invention provides methods of treating, reducing, preventing, or inhibiting symptoms of diabetes and/or lowering plasma levels of HbA1c by co-administration of therapeutic or... |
|
|
US20150099742 |
PHANTOM PHENOMENA TREATMENT
The present invention relates to a substance for the treatment of the phantom phenomena of tinnitus and/or phantom pain, a method for the diagnosis and for the treatment of these phantom phenomena. |
|
|
US20120302554 |
PHANTOM PHENOMENA TREATMENT
The present invention relates to a substance for the treatment of the phantom phenomena of tinnitus and/or phantom pain, a method for the diagnosis and for the treatment of these phantom phenomena. |
|
|
US20120142675 |
Methods for Treating Diseases of the Retina
Disclosed herein is a method of treating disorders of the retina comprising administering to a patient in need of such treatment a compound selected from the group consisting of olanzapine,... |
|
|
US20140349999 |
METHODS FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN
The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present... |
|
|
US20120077800 |
Methods for Treating Antipsychotic-Induced Weight Gain
The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present... |
|
|
US20140243322 |
BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME
Described herein are compounds capable of modulating one or more biomolecules substantially simultaneously, e.g., modulating two or more binding domains (e.g., bromodomains) on a protein or on... |
|
|
US20110091544 |
Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
Small tablets for use in procedural sedation, anxiolysis and analgesia comprising the combination sufentanil and triazolam administered via the oral transmucosal route and methods for using the... |
|
|
US20090060871 |
ADMINISTRATION OF AGONIST-ANTAGONIST IN OPIOID-DEPENDENT PATIENTS
A method for reducing psychological opioid dependence includes selecting a patient addicted to an opioid and administering to the patient an opioid agonist-antagonist for at least 14 days, thereby... |
|
|
US20120129835 |
SCHIZOPHRENIA METHODS AND COMPOSITIONS
Methods of preparing and using neural cells derived from human induced pluripotent stem cell (hiPSCs), particularly hiPSCs derived from subjects with schizophrenia are provided. The hiPSC-derived... |
|
|
US20150031655 |
COMBINATION OF LIVER X RECEPTOR MODULATOR AND ESTROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF AGE-RELATED DISEASES
The disclosure provides a method of treating a mammal afflicted with an age-related disorder, comprising administering to the mammal a combination of liver X receptor (LXR) modulator and estrogen... |
|
|
US20150157558 |
METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE FORM
A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form. |
|
|
US20140073562 |
NASAL DELIVERY
A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a... |
|
|
US20140018295 |
NASAL DELIVERY
A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a... |
|
|
US20130143872 |
INJECTABLE FORMULATION OF A REVERSE TRANSCRIPTASE INHIBITOR FOR THE TREATMENT CANCER
This invention relates to a composition formulated into a parenteral or injectable dosage form for the treatment of cancer, more particularly, this invention relates to a composition formulated... |
|
|
US20120040961 |
PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS
The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), polo kinase 1, 2, 3, or 4, Ack1, Ack2, AbI,... |